Gordian Group served as financial advisor to Dyadic to explore its strategic options as they related to the possible sale of all, or part, of its assets and/or the licensing of the Company’s technology and intellectual property.
Case Study
Dyadic
CLIENT: Special Committee of the Board of Dyadic International, Inc.
Industries
TechnologyBusiness Profiles
Private Equity / Entrepreneur RepresentationsSituation
Dyadic is a leading-edge early stage biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries.
Engagement
Gordian Group served as financial advisor to Dyadic to explore its strategic options as they related to the possible sale of all or part of its assets, and/or the licensing on an exclusive or nonexclusive basis of certain parts of the Company’s technology and intellectual property.
Outcome
Gordian Group advised Dyadic in the execution of its licensing strategy.